Outcomes of adjuvant lymph node field radiotherapy and immunotherapy for stage III melanoma
In patients with stage III melanoma, adjuvant lymph-node field radiotherapy combined with immunotherapy seems to be associated with longer disease-free survival, with acceptable tolerance. However, these results need to be confirmed by long-term and prospective studies.
Authors
- Andréa Desagneaux
- Mathieu Laramas (ORCID: https://orcid.org/0000-0002-0918-8471)
- Alexandre Bellier (ORCID: https://orcid.org/0000-0003-0907-0315)
- Camille Verry (ORCID: https://orcid.org/0000-0002-9362-7624)
- J. Charles (ORCID: https://orcid.org/0000-0003-4667-6009)
- Léa Marxgut
- Stéphane Mouret (ORCID: https://orcid.org/0000-0003-3880-973X)
Institutions
- Centre Hospitalier Universitaire de Grenoble (FR)
Publication Details
- Journal
- Cancer/Radiothérapie
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1016/j.canrad.2024.03.006
- Citations
- 1
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.28